Balkwill F - Search Results

1

Tumor necrosis factor alpha as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose.

Harrison ML, Obermueller E, Maisey NR, Hoare S, Edmonds K, Li NF, Chao D, Hall K, Lee C, Timotheadou E, Charles K, Ahern R, King DM, Eisen T, Corringham R, DeWitte M, Balkwill F, Gore M. Harrison ML, et al. Among authors: balkwill f. J Clin Oncol. 2007 Oct 10;25(29):4542-9. doi: 10.1200/JCO.2007.11.2136. J Clin Oncol. 2007. PMID: 17925549 Clinical Trial.

2

Low-dose IFN-gamma induces tumor MHC expression in metastatic malignant melanoma.

Propper DJ, Chao D, Braybrooke JP, Bahl P, Thavasu P, Balkwill F, Turley H, Dobbs N, Gatter K, Talbot DC, Harris AL, Ganesan TS. Propper DJ, et al. Among authors: balkwill f. Clin Cancer Res. 2003 Jan;9(1):84-92. Clin Cancer Res. 2003. PMID: 12538455 Clinical Trial.

3

An anti-tumor necrosis factor-alpha antibody inhibits the development of experimental skin tumors.

Scott KA, Moore RJ, Arnott CH, East N, Thompson RG, Scallon BJ, Shealy DJ, Balkwill FR. Scott KA, et al. Mol Cancer Ther. 2003 May;2(5):445-51. Mol Cancer Ther. 2003. PMID: 12748306

4

Tumour necrosis factor alpha: a potential target for the therapy of solid tumours.

Szlosarek PW, Balkwill FR. Szlosarek PW, et al. Lancet Oncol. 2003 Sep;4(9):565-73. doi: 10.1016/s1470-2045(03)01196-3. Lancet Oncol. 2003. PMID: 12965278 Review.

5

A multicentre phase II trial of bryostatin-1 in patients with advanced renal cancer.

Madhusudan S, Protheroe A, Propper D, Han C, Corrie P, Earl H, Hancock B, Vasey P, Turner A, Balkwill F, Hoare S, Harris AL. Madhusudan S, et al. Among authors: balkwill f. Br J Cancer. 2003 Oct 20;89(8):1418-22. doi: 10.1038/sj.bjc.6601321. Br J Cancer. 2003. PMID: 14562010 Free PMC article. Clinical Trial.

6

A modified medium that significantly improves the growth of human normal ovarian surface epithelial (OSE) cells in vitro.

Li NF, Wilbanks G, Balkwill F, Jacobs IJ, Dafou D, Gayther SA. Li NF, et al. Among authors: balkwill f. Lab Invest. 2004 Jul;84(7):923-31. doi: 10.1038/labinvest.3700093. Lab Invest. 2004. PMID: 15077121 Free article.

7

A phase II study of etanercept (Enbrel), a tumor necrosis factor alpha inhibitor in patients with metastatic breast cancer.

Madhusudan S, Foster M, Muthuramalingam SR, Braybrooke JP, Wilner S, Kaur K, Han C, Hoare S, Balkwill F, Talbot DC, Ganesan TS, Harris AL. Madhusudan S, et al. Among authors: balkwill f. Clin Cancer Res. 2004 Oct 1;10(19):6528-34. doi: 10.1158/1078-0432.CCR-04-0730. Clin Cancer Res. 2004. PMID: 15475440 Clinical Trial.

8

Smoldering and polarized inflammation in the initiation and promotion of malignant disease.

Balkwill F, Charles KA, Mantovani A. Balkwill F, et al. Cancer Cell. 2005 Mar;7(3):211-7. doi: 10.1016/j.ccr.2005.02.013. Cancer Cell. 2005. PMID: 15766659 Free article. Review. No abstract available.

9

Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK.

Hagemann T, Wilson J, Kulbe H, Li NF, Leinster DA, Charles K, Klemm F, Pukrop T, Binder C, Balkwill FR. Hagemann T, et al. Among authors: balkwill fr. J Immunol. 2005 Jul 15;175(2):1197-205. doi: 10.4049/jimmunol.175.2.1197. J Immunol. 2005. PMID: 16002723

10

Study of etanercept, a tumor necrosis factor-alpha inhibitor, in recurrent ovarian cancer.

Madhusudan S, Muthuramalingam SR, Braybrooke JP, Wilner S, Kaur K, Han C, Hoare S, Balkwill F, Ganesan TS. Madhusudan S, et al. Among authors: balkwill f. J Clin Oncol. 2005 Sep 1;23(25):5950-9. doi: 10.1200/JCO.2005.04.127. J Clin Oncol. 2005. PMID: 16135466 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

305 results

Search Page

Filters